$3.71
-0.21-5.36%
Pre-Market: Jul 9, 4:00 PM EDT
15 minutes delayed
Aprea Therapeutics
APRENASDAQ
want to know what
the Bulls & Bears Say?
Aprea Therapeutics (NASDAQ:APRE) Stock, Analyst Ratings, Price Targets, Forecasts
Aprea Therapeutics Inc has a consensus price target of $9.33 based on the ratings of 8 analysts. The high is $20 issued by HC Wainwright & Co. on June 24, 2024. The low is $2 issued by HC Wainwright & Co. on March 16, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 24, 2024, June 17, 2024, and May 14, 2024, respectively. With an average price target of $20 between HC Wainwright & Co., there's an implied 439.08% upside for Aprea Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Maxim Group
HC Wainwright & Co.
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Aprea Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2024 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 196.5% | Wedbush | Robert Driscoll | $9 → $11 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | $20 → $20 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 439.08% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2023 | Buy Now | 331.27% | Maxim Group | Jason McCarthy | → $16 | Initiates | → Buy | Get Alert |
| 10/10/2022 | Buy Now | -19.14% | HC Wainwright & Co. | Joseph Pantginis | → $60 | Assumes | → Buy | Get Alert |
| 07/08/2022 | Buy Now | -19.14% | Wedbush | Robert Driscoll | → $60 | Initiates | → Outperform | Get Alert |
| 03/16/2022 | Buy Now | -46.09% | HC Wainwright & Co. | Andrew Fein | $80 → $40 | Maintains | Neutral | Get Alert |
| 03/16/2022 | Buy Now | 7.82% | RBC Capital | Gregory Renza | $100 → $80 | Maintains | Sector Perform | Get Alert |
| 08/20/2021 | Buy Now | — | JP Morgan | Jessica Fye | — | Downgrade | Neutral → Underweight | Get Alert |
| 08/16/2021 | Buy Now | — | Berenberg | Esther Hong | — | Downgrade | Buy → Hold | Get Alert |
| 08/16/2021 | Buy Now | 7.82% | HC Wainwright & Co. | Andrew Fein | — | Maintains | Neutral | Get Alert |
| 08/13/2021 | Buy Now | 34.77% | RBC Capital | Gregory Renza | — | Maintains | Sector Perform | Get Alert |
| 08/13/2021 | Buy Now | -19.14% | Morgan Stanley | Jeffrey Hung | — | Downgrade | Equal-Weight → Underweight | Get Alert |
FAQ
What is the target price for Aprea Therapeutics (APRE) stock?
The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by HC Wainwright & Co. on June 24, 2024. The analyst firm set a price target for $20.00 expecting APRE to rise to within 12 months (a possible 410.20% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by HC Wainwright & Co., and Aprea Therapeutics reiterated their buy rating.
When was the last upgrade for Aprea Therapeutics (APRE)?
There is no last upgrade for Aprea Therapeutics
When was the last downgrade for Aprea Therapeutics (APRE)?
The last downgrade for Aprea Therapeutics Inc happened on August 20, 2021 when JP Morgan changed their price target from N/A to N/A for Aprea Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on June 24, 2024 so you should expect the next rating to be made available sometime around June 24, 2025.
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $20.00 to $20.00. The current price Aprea Therapeutics (APRE) is trading at is $3.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.